Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBITDA (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of EBITDA readings, the most recent being -$164000.0 for Q4 2025.

  • On a quarterly basis, EBITDA rose 96.76% to -$164000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$197.2 million, a 98.48% decrease, with the full-year FY2025 number at -$197.2 million, down 98.48% from a year prior.
  • EBITDA hit -$164000.0 in Q4 2025 for Tandem Diabetes Care, up from -$19.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $10.2 million in Q4 2021 to a low of -$128.5 million in Q1 2025.
  • Median EBITDA over the past 5 years was -$18.9 million (2024), compared with a mean of -$29.9 million.
  • Biggest five-year swings in EBITDA: skyrocketed 162.4% in 2021 and later crashed 960.91% in 2022.
  • Tandem Diabetes Care's EBITDA stood at $10.2 million in 2021, then crashed by 223.86% to -$12.6 million in 2022, then tumbled by 109.64% to -$26.4 million in 2023, then surged by 80.85% to -$5.1 million in 2024, then surged by 96.76% to -$164000.0 in 2025.
  • The last three reported values for EBITDA were -$164000.0 (Q4 2025), -$19.7 million (Q3 2025), and -$48.7 million (Q2 2025) per Business Quant data.